BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 36946306)

  • 1. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
    Muddebihal A; Khurana A; Sardana K
    Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK-STAT pathway inhibitors in dermatology.
    Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
    An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
    Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
    Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
    Niu C; Xie H; Aisa HA
    Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
    Ryguła I; Pikiewicz W; Kaminiów K
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects.
    Klein B; Treudler R; Simon JC
    J Dtsch Dermatol Ges; 2022 Jan; 20(1):19-24. PubMed ID: 34962052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK inhibitors in dermatology: The promise of a new drug class.
    Damsky W; King BA
    J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
    Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
    Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK/STAT pathway modulation: Does it work in dermatology?
    Gündüz Ö
    Dermatol Ther; 2019 May; 32(3):e12903. PubMed ID: 30964573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
    Sardana K; Muddebihal A; Khurana A
    Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
    Cinats A; Heck E; Robertson L
    Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical Janus kinase inhibitors: A review of applications in dermatology.
    Hosking AM; Juhasz M; Mesinkovska NA
    J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
    Kahn J; Deverapalli SC; Rosmarin D
    Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Baricitinib in Dermatology.
    Zhang J; Qi F; Dong J; Tan Y; Gao L; Liu F
    J Inflamm Res; 2022; 15():1935-1941. PubMed ID: 35330989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
    Dogra S; Sharma A; Mehta H; Sarkar R
    Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.